



## General Meeting – Chairman’s Script

**30 June 2023 – Sydney, Australia: PharmAust Limited (ASX: PAA & PAAO)** advises that the General Meeting of the Shareholders of PharmAust Limited (“EGM”) will be held today at Level 13, 60 Castlereagh Street, Sydney, New South Wales at 10:30am (AEST).

### Chairman’s Script

The Company refers to the previous Notice of General Meeting published on 26 May 2023 (“Notice of General Meeting/Proxy Form”).

In accordance with ASX Listing Rule 3.13.3, the Company attaches the Chairman’s script in relation to the EGM commencing at 10:30am (AEST) today, in person at Level 13, 60 Castlereagh Street, Sydney, New South Wales.

The results of the EGM will be communicated on ASX shortly after the conclusion of the meeting.

This ASX release has been approved for release by Sam Wright on behalf of the Board of Directors.

### Enquiries:

**Anusha Aubert**  
**Investor Relations**  
**[investorenquiries@pharmaust.com](mailto:investorenquiries@pharmaust.com)**

**P +61 (8) 9202 6814**  
**F +61 (8) 9467 6111**  
**W [www.pharmaust.com](http://www.pharmaust.com)**



### About PharmAust Limited:

PharmAust Limited is listed on the Australian Securities Exchange (PAA) and the Frankfurt Stock Exchange (ECQ). PAA is a clinical-stage company developing therapeutics for both humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development. These efforts are supported by PAA’s subsidiary, Epichem, a highly successful contract medicinal chemistry company that generated \$3.4 million in sales of goods & services in FY 2022.

PAA’s lead drug candidate is monepantel (MPL), a novel, a potent and safe inhibitor of the mTOR pathway – a pathway having key influences in cancer growth and neurodegenerative diseases. MPL has been evaluated in Phase 1 clinical trials in humans and Phase 2 clinical trials in dogs. MPL treatment was well-tolerated in humans, demonstrating preliminary evidence of anticancer activity. MPL showed objective anticancer activity in dogs. PAA is uniquely positioned to commercialise MPL for treating human and veterinary cancers and neurodegenerative diseases as it advances a reformulated version of this drug through Phase 1 and 2 clinical trials.

# PHARMAUST LIMITED

**General Meeting of Shareholders  
30 June 2023 at 10:30 am (AEST)**

---

## **Welcome**

Good morning Ladies and Gentlemen.

My name is Robert Bishop.

I am an Executive Director of PharmAust Limited and I welcome you to this General Meeting of Shareholders.

Dr Aston is in the UK and cannot attend the EGM in person and I have been appointed to chair today's meeting.

## **Opening**

As it is past the appointed time of 10:30am Australian Eastern Standard Time and a quorum is present, **I declare this meeting open.**

## **Introduction Directors**

I am joined by fellow director Mr Sam Wright.

## **Apologies**

Dr Roger Aston and Mr Neville Bassett both send their apologies.

## **Attendance Register**

I draw your attention to the attendance register and ask you to register your attendance if you haven't already done so.

## **Move to formal part - Notice of Meeting**

The notice of meeting has been circulated to all shareholders.

I do not intend to read the notice in full. I will table it as read.

I can advise that the company has received valid proxies as per the slide on the monitor.

Where entitled, the Chairman's proxy votes will be cast in favour of each of the resolutions.

The ASX recommendations provide that voting on resolutions should be conducted by a poll rather than a show of hands. I will read today's resolutions, and then a representative from Computershare will assist with voting via poll.

The final results of the poll will be announced to the ASX.

## **Moving to the resolutions to be put to shareholders today**

# PHARMAUST LIMITED

## **RESOLUTION 1 – RATIFICATION OF ISSUE OF PLACEMENT SECURITIES TO UNRELATED PARTIES UNDER LISTING RULE 7.1**

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

*"That the issue of 29,244,294 Placement Shares and 15,000,000 Placement Options to institutional investors on 11 May 2023 as part of a placement utilising Listing Rule 7.1 is approved under and for the purposes of Listing Rule 7.4 and for all other purposes, on the terms set out in the Explanatory Statement."*

Is there any discussion on the resolution?

We will now move on to the next resolution.

## **RESOLUTION 2 – RATIFICATION OF ISSUE OF PLACEMENT SHARES TO UNRELATED PARTIES UNDER LISTING RULE 7.1A**

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

*"That the issue of 755,706 Placement Shares to institutional investors on 11 May 2023 as part of a placement utilising Listing Rule 7.1A is approved under and for the purposes of Listing Rule 7.4 and for all other purposes, on the terms set out in the Explanatory Statement."*

Is there any discussion on the resolution?

We will now move on to the next resolution.

## **RESOLUTION 3 - APPROVAL TO ISSUE PLACEMENT SECURITIES TO NEVILLE BASSETT**

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

*"That the issue up to 500,000 Placement Shares and 250,000 Placement Options to Neville Bassett or his nominees is approved under and for the purposes of Listing Rule 10.11 and for all other purposes, on the terms set out in the Explanatory Statement."*

Is there any discussion on the resolution?

We will now move on to the next resolution.

# PHARMAUST LIMITED

## **RESOLUTION 4 – APPROVAL TO ISSUE PLACEMENT SECURITIES TO SAM WRIGHT**

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

*"That the issue up to 500,000 Placement Shares and 250,000 Placement Options to Sam Wright or his nominees is approved under and for the purposes of Listing Rule 10.11 and for all other purposes, on the terms set out in the Explanatory Statement."*

Is there any discussion on the resolution?

We will now move on to the next resolution.

## **RESOLUTION 5 – APPROVAL TO ISSUE PLACEMENT SECURITIES TO ROBERT BISHOP**

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

*"That the issue up to 300,000 Placement Shares and 150,000 Placement Options to Robert Bishop or his nominees is approved under and for the purposes of Listing Rule 10.11 and for all other purposes, on the terms set out in the Explanatory Statement."*

Is there any discussion on the resolution?

We will now move on to the next resolution.

## **RESOLUTION 6 – RATIFICATION OF ISSUE OF ADVISER OPTIONS**

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

*"That the issue of 2,730,000 Adviser Options to Baker Young Ltd on 11 May 2023 under Listing Rule 7.1 is approved under and for the purposes of Listing Rule 7.4 and for all other purposes, on the terms set out in the Explanatory Statement."*

Is there any discussion on the resolution?

We will now move on to the next resolution.

# PHARMAUST LIMITED

## RESOLUTION 7 – RATIFICATION OF ISSUE OF ADVISER SHARES

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

*"That the issue of 562,557 Shares to Spark Plus Pte Ltd on 11 May 2023 under Listing Rule 7.1 is approved under and for the purposes of Listing Rule 7.4 and for all other purposes, on the terms set out in the Explanatory Statement."*

Is there any discussion on the resolution?

We will now move on to the next resolution.

## RESOLUTION 8 – AMENDMENT TO CONSTITUTION

To consider and, if thought fit, to pass, with or without amendment, the following resolution as a **special resolution**:

*"That, for the purposes of section 136(2) of the Corporations Act and for all other purposes, approval is given for the Company to amend its existing Constitution, with effect from the close of the Meeting, to allow for the use of technology at general meetings and distribution of meeting-related documents."*

Is there any discussion on the resolution?

**We will now move to conduct the poll for the resolutions.**

I now declare the poll open.

The poll is being conducted on each of the resolutions to be considered today.

If you have voted by proxy prior to the meeting you do not need to complete a Voting Card, your vote has already been recorded.

You will note on your Voting Card that you may vote 'for', 'against' or 'abstain' on each of the resolutions.

If you wish to cast ALL of your votes either 'for', 'against' or 'abstain' you can do so by placing a mark in the appropriate box beside each resolution.

If you are in attendance today as a proxy holder for a holder that recorded 'open' votes, these votes are yours to cast at your discretion and you can do so by marking your voting card on each resolution accordingly.

If anyone has any questions about this process please raise your hand.

When you have finished filling in your Voting Card a representative from Computershare will collect it.

# PHARMAUST LIMITED

(Pause)

Have all persons who intend to vote now voted?

It appears as though the voting process has been completed.

I therefore declare the poll closed.

The final results of voting will be released to the stock exchange later today.

---

## **Closure**

That concludes the formal part of business to be conducted today.

Thank you for your attendance ladies and gentlemen and I declare the meeting closed at \_\_\_\_\_ o'clock.